Free Trial

U.S. stocks begin to dip as Gilead.........>

EQUITIES
EQUITIES: U.S. stocks begin to dip as Gilead Sciences reports results from the
Phase 3 Trial of Remdesivir in patients with COVID-19, with the upshot as seen
in Bloomberg headline: "GILEAD FALLS 5%; 10-DAY REGIMEN FAILS TO REACH
SIGNIFIGANCE"

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.